Skip to main content

LSBC Q2 Revenues Increased, But Under $1M

NEW YORK, July 23 - Large Scale Biology reported revenues of $0.9 million for the second quarter, compared to $490,000 in the same period last year.


The Vacaville, Calif., company had a net loss of $6.2 million for the quarter, compared to $9.6 million for the second quarter of 2002.


LSBC's R&D expenses narrowed to $2.8 million, from $5.9 million in the year-ago quarter. These expense reductions follow a restructuring program announced in June, in which the company plans to cut costs $5 million within the year. 


At the end of the second quarter, the company had $15.0 million in cash and marketable securities.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.